Despite earlier studies suggesting a relatively low overall incidence of TD AEs with ipilimumab (a cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) monoclonal antibody) compared to other ICIs (24, 25), this present study identified a strong reporting signal for hyperthyroidism, highlighting the need for clinical vigilance. Here, CTLA4 is linked to hyperthyroidism.